EGFR and non-small cell lung carcinoma: Our research demonstrated the real-world efficacies of sequential osimertinib treatment in advanced and recurrence EGFR-mutant NSCLC patients harboring acquired T790M mutation after progressive disease to first-line EGFR-TKIs.